Early and Accurate Diagnosis of Melanoma is Critical for Long-Term Survival.1

What is myPath® Melanoma?

Myriad Genetic Laboratories has developed myPath® Melanoma, a clinically validated test to be used as an adjunct to histopathology when the distinction between a benign nevus and a malignant melanoma cannot be made confidently by histopathology alone. Reasons that definitive diagnosis may not be achievable by histopathology include indeterminate or ambiguous histopathologic features, diagnostic disagreement among physicians, or indications that additional workup or consultation are necessary.

The test measures the expression of 23 genes by qRT-PCR methodology and distinguishes melanoma from nevi with a sensitivity of 90-94% and a specificity of 91-96%. 7,29,30

Watch Dr. Loren Clarke answer questions about myPath Melanoma

Testing Process

In light of the public health preparedness efforts currently underway, Myriad’s top priorities are protecting the health and safety of employees, our customers, and their patients.

Click here to learn more about our measures to help keep you and your patients safe.

How the myPath Melanoma Test Works

The myPath Melanoma test measures 23 genes for which expression patterns differ between malignant melanoma and benign nevi. These genes are involved in cell differentiation, cell signaling, and immune response signaling.

Covered by Medicare

9 out of 10 patients pay $0

*after insurance and financial assistance. $95 is the average out-of-pocket cost for patients with any cost sharing responsibility.

Subscribe To Our Email Updates

Subscribe for More Info

Stay in Touch

We will keep you updated with product enhancements and new product information to help you provide the best
possible care for your patients

General Email Subscribe

Myriad is committed to protecting and respecting your privacy, and we’ll only use your personal information to administer your account and to provide the products and services you requested from us.

From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please tick below to say how you would like us to contact you:

You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.

By clicking submit below, you consent to allow Myriad to store and process the personal information submitted above to provide you the content requested.
Hidden Fields

"Melanocytic lesions continue to pose significant interpretive problems to histopathologists."

Lorenzo Cerroni, et al